Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial

Novo Nordisk stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target.

The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning.

Eli Lilly‘s stock rose 2.1% in premarket trading.

Novo is exploring additional trials to test CagriSema, including higher-dose combinations, it said.

This is breaking news. Please refresh for updates.

Source

World

‘Resumption of hostilities’: seized ship, vessel attacks push U.S.-Iran ceasefire toward brink

April 20, 2026

A person points at a page on the Marinetraffic website that shows commercial boats traffic on the edge of the Strait of Hormuz near the Iranian coast, in Paris on March 4, 2026. Julien De Rosa | Afp | Getty Images Fifty days into the U.S.-Israel war with Iran, tensions escalated again after clashes in […]

World

European stocks set to slump as Gulf tanker attacks threaten ceasefire

April 20, 2026

Traders work on the floor of the New York Stock Exchange during morning trading on April 17, 2026 in New York City. Michael M. Santiago | Getty Images LONDON — European stocks are expected to fall at the start of the new trading week on fears that a re-escalation of U.S.-Iran tensions over the weekend […]

World

CNBC Daily Open: Ship struck and Strait shut

April 20, 2026

Ships and tankers in the Strait of Hormuz off the coast of Musandam, Oman, April 18, 2026. Stringer | Reuters Hello, this is Leonie Kidd writing to you from Singapore (yes, that’s right — not London this week!). Welcome to another edition of CNBC’s Daily Open. Flying into Singapore over the weekend gave me a […]